Bio-Techne launches cell and gene therapy portfolio

Create PDF

March 2019—Bio-Techne announced the launch of its cell and gene therapy portfolio. The portfolio includes growth-manufacturing-grade cytokines and growth factors, GMP small molecules, GMP media, and antibodies for flow cytometry and immunocytochemical characterization. The company’s Cloudz Cell Activation Kits and the Simple Plex immunoassays technologies are designed to expedite cell expansion and improve product quality control, respectively.